2HUMBERT M,SITBON 0,SIM0NNEAU G. Treatment of pulmo-nary arterial hypertension [ J ]. N Engl J Med ^2004 , 351 ( 14):1425 - 1436.
3CLAPP LH, FINNEY P,TURCATO S, et al. Differential effectsof stable prostacyclin analogs on smooth muscle proliferation andcyclic AMP generation in human pulmonary artery [J]. Am J Re-spir Cell Mol 5w/,2002 ,26(2) :194 -201.
4BARST RJ, RUBIN LJ, LONG WAal. A comparison of con-tinuous intravenous epoprostenol ( prostacyclin) with conventionaltherapy for primary pulmonary hypertension[ J] ? N Engl J Med,1996,334(5) :296 -301.
5TUDEH RM, COOL CD, GERACI MW.ei al. Prostacyclin syn-thase expression is decreased in lungs from patients with severepulmonary hypertension [ J ]. Am J Respir Crit Care Medy 1999 ,159(6) :1925 - 1932.
6WHITTLE BJ, SILVERSTEIN AM, MOTTO LA DM,et al. Bind-ing and activity of the prostacyclin receptor (IP) agonists,trepro-stinil and iloprost, at human prostanoid receptors : treprostinil is apotent DPI and EP2 agonist [ J ]. Biochem Pharmacol, 2012 , 84(1);68 -75.
7VANE JR,BOTTING RM. Pharmacodynamic profile of prostacyc-lin[J]. Am J Cardiol ,1995,15 (3) :3A - 10A.
8LI Y, CONNOLLY M,NAGARAJ C,et al. Peroxisome prolifera-tor-activated receptor-b/d, the acute signaling factor in prostacyc-lin-induced pulmonary vasodilation[ J] . Am J Respir Cell Mol Bi-o/,2012,46(3) :372 -379.
9WADE M, BAKER FJ,ROSCIGNO R,e( al. Absolute bioavail-ability and pharmacokinetics of treprostinil sodium administeredby acute subcutaneous infusion [ J ]. J Clin Pharmacol, 2004 ,44(1):83 -88.
10NELSEN AC, LALIBERTE KL,ZACCARDELLI DS,e( al. Phar-macokinetics of inhaled treprostinil sodium in healthy volunteers[J]. Am J Respir Crit Care Wee/,2010,181 : Abstract A3348.
